Browse AXL

Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF00041 Fibronectin type III domain
PF07714 Protein tyrosine kinase
Function

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, ALX binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. ; FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and lymphocytic choriomeningitis virus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. ; FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001764 neuron migration
GO:0001779 natural killer cell differentiation
GO:0001818 negative regulation of cytokine production
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001961 positive regulation of cytokine-mediated signaling pathway
GO:0001974 blood vessel remodeling
GO:0002237 response to molecule of bacterial origin
GO:0002262 myeloid cell homeostasis
GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0006907 pinocytosis
GO:0006909 phagocytosis
GO:0006979 response to oxidative stress
GO:0007283 spermatogenesis
GO:0007548 sex differentiation
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019058 viral life cycle
GO:0021700 developmental maturation
GO:0021885 forebrain cell migration
GO:0030098 lymphocyte differentiation
GO:0030100 regulation of endocytosis
GO:0030101 natural killer cell activation
GO:0030168 platelet activation
GO:0030260 entry into host cell
GO:0030540 female genitalia development
GO:0030900 forebrain development
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031589 cell-substrate adhesion
GO:0031668 cellular response to extracellular stimulus
GO:0032496 response to lipopolysaccharide
GO:0032609 interferon-gamma production
GO:0032640 tumor necrosis factor production
GO:0032649 regulation of interferon-gamma production
GO:0032680 regulation of tumor necrosis factor production
GO:0032689 negative regulation of interferon-gamma production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032814 regulation of natural killer cell activation
GO:0032816 positive regulation of natural killer cell activation
GO:0032823 regulation of natural killer cell differentiation
GO:0032825 positive regulation of natural killer cell differentiation
GO:0034101 erythrocyte homeostasis
GO:0034446 substrate adhesion-dependent cell spreading
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0035455 response to interferon-alpha
GO:0035457 cellular response to interferon-alpha
GO:0042542 response to hydrogen peroxide
GO:0042698 ovulation cycle
GO:0043277 apoptotic cell clearance
GO:0043491 protein kinase B signaling
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0044409 entry into host
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045807 positive regulation of endocytosis
GO:0046660 female sex differentiation
GO:0046718 viral entry into host cell
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048232 male gamete generation
GO:0048469 cell maturation
GO:0048511 rhythmic process
GO:0048548 regulation of pinocytosis
GO:0048549 positive regulation of pinocytosis
GO:0048608 reproductive structure development
GO:0048771 tissue remodeling
GO:0048806 genitalia development
GO:0048872 homeostasis of number of cells
GO:0050817 coagulation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050878 regulation of body fluid levels
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051402 neuron apoptotic process
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0060068 vagina development
GO:0060627 regulation of vesicle-mediated transport
GO:0060759 regulation of response to cytokine stimulus
GO:0060760 positive regulation of response to cytokine stimulus
GO:0061458 reproductive system development
GO:0070301 cellular response to hydrogen peroxide
GO:0070997 neuron death
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071496 cellular response to external stimulus
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071887 leukocyte apoptotic process
GO:0097028 dendritic cell differentiation
GO:0097048 dendritic cell apoptotic process
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000668 regulation of dendritic cell apoptotic process
GO:2000669 negative regulation of dendritic cell apoptotic process
Molecular Function GO:0001618 virus receptor activity
GO:0001786 phosphatidylserine binding
GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005543 phospholipid binding
GO:0017022 myosin binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0032036 myosin heavy chain binding
GO:0043548 phosphatidylinositol 3-kinase binding
GO:0046982 protein heterodimerization activity
GO:0072341 modified amino acid binding
Cellular Component GO:0018995 host
GO:0033643 host cell part
GO:0043657 host cell
GO:0044215 other organism
GO:0044216 other organism cell
GO:0044217 other organism part
GO:0044228 host cell surface
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-162582: Signal Transduction
R-HSA-194138: Signaling by VEGF
R-HSA-4420097: VEGFA-VEGFR2 Pathway
Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AXL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AXL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AXL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.3910.00354
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.790.27
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0980.368
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2010.658
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.030.99
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4160.897
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2360.678
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3280.823
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0810.962
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.6860.338
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.1080.419
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3690.00844
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AXL in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.46.80.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.48.5-1.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AXL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AXL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AXL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AXL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AXL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AXL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAXL
NameAXL receptor tyrosine kinase
Aliases UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AXL collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.